What Researchers Did
Researchers conducted a study across 10 centres in Italy to observe how hyperbaric oxygen therapy (HBOT) is currently used, including the reasons for treatment and how it is given.
What They Found
The study included 327 patients, with 73.7% receiving elective treatments and 26.3% urgent care. The most common reasons for HBOT were sudden hearing loss (35.8%), carbon monoxide poisoning (19.9%), and soft tissue infections (12.2%). Treatments typically involved 16 sessions at a median pressure of 2.5 ATA, with no serious adverse events reported.
What This Means for Canadian Patients
This study provides insights into HBOT use for conditions like carbon monoxide poisoning, which is a Health Canada-recognised indication. For Canadian patients with sudden hearing loss or certain soft tissue infections, these findings suggest how HBOT protocols might be structured and the types of outcomes to expect. The observed safety profile, with no serious adverse events, is also reassuring for patients considering HBOT.
Canadian Relevance
This study was conducted in Italy and does not involve Canadian authors or centres. However, it covers carbon monoxide poisoning, which is a Health Canada-recognised indication for hyperbaric oxygen therapy.
Study Limitations
As an observational study specific to Italy, this research describes current practices but does not compare HBOT to other treatments or evaluate long-term patient outcomes.